{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:02:59Z","timestamp":1783350179035,"version":"3.54.6"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jocn.2021.12.025","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T11:31:32Z","timestamp":1646998292000},"page":"190-203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Effects of cilostazol treatment for patients with aneurysmal subarachnoid hemorrhage: A meta-analysis of 14 studies"],"prefix":"10.1016","volume":"99","author":[{"given":"Lian","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiming","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peihong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jocn.2021.12.025_b0005","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1001\/jamaneurol.2019.0006","article-title":"Worldwide incidence of aneurysmal subarachnoid hemorrhage according to region, time period, blood pressure, and smoking prevalence in the population: a systematic review and meta-analysis","volume":"76","author":"Etminan","year":"2019","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.jocn.2021.12.025_b0010","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4037\/aacnacc2018491","article-title":"Aneurysmal subarachnoid hemorrhage and vasospasm","volume":"29","author":"Burns","year":"2018","journal-title":"AACN Adv Crit Care"},{"key":"10.1016\/j.jocn.2021.12.025_b0015","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1016\/j.wneu.2020.10.008","article-title":"Risk factors for cerebral vasospasm in aneurysmal subarachnoid hemorrhage: a population-based study of 8346 patients","volume":"145","author":"Rumalla","year":"2021","journal-title":"World Neurosurg"},{"issue":"13","key":"10.1016\/j.jocn.2021.12.025_b0020","doi-asserted-by":"crossref","first-page":"e1819","DOI":"10.1212\/WNL.0000000000010618","article-title":"Short- and long-term outcome of patients with aneurysmal subarachnoid hemorrhage","volume":"95","author":"Roquer","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jocn.2021.12.025_b0025","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12883-021-02303-8","article-title":"Effectiveness comparisons of drug therapies for postoperative aneurysmal subarachnoid hemorrhage patients: network meta-analysis and systematic review","volume":"21","author":"Yu","year":"2021","journal-title":"BMC Neurol"},{"issue":"1-2","key":"10.1016\/j.jocn.2021.12.025_b0030","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jns.2013.10.027","article-title":"Effect of cilostazol in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis","volume":"336","author":"Niu","year":"2014","journal-title":"J Neurol Sci"},{"issue":"2","key":"10.1016\/j.jocn.2021.12.025_b0035","first-page":"33","article-title":"Therapeutic benefit of cilostazol in patients with aneurysmal subarachnoid hemorrhage: a meta-analysis of randomized and nonrandomized studies","volume":"10","author":"Qureshi","year":"2018","journal-title":"J Vasc Interv Neurol"},{"issue":"11","key":"10.1016\/j.jocn.2021.12.025_b0040","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.06.027","article-title":"Efficacy of cilostazol in prevention of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: a meta-analysis","volume":"27","author":"Saber","year":"2018","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.jocn.2021.12.025_b0045","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jocn.2021.04.044","article-title":"Cilostazol administration for subarachnoid hemorrhage: A meta-analysis of randomized controlled trials","volume":"89","author":"Chen","year":"2021","journal-title":"J Clin Neurosci"},{"issue":"6","key":"10.1016\/j.jocn.2021.12.025_b0050","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00415-019-09198-z","article-title":"Effectiveness and feasibility of cilostazol in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis","volume":"267","author":"Shan","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2021.12.025_b0055","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.wneu.2021.02.069","article-title":"Role of cilostazol in prevention of vasospasm after aneurysmal subarachnoid hemorrhage-a systematic review, meta-analysis, and trial sequential analysis","volume":"150","author":"Bohara","year":"2021","journal-title":"World Neurosurg"},{"issue":"1-2","key":"10.1016\/j.jocn.2021.12.025_b0060","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000445509","article-title":"Effect of cilostazol on cerebral vasospasm and outcome in patients with aneurysmal subarachnoid hemorrhage: a randomized, double-blind, Placebo-controlled trial","volume":"42","author":"Matsuda","year":"2016","journal-title":"Cerebrovasc Dis"},{"issue":"1","key":"10.1016\/j.jocn.2021.12.025_b0065","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3171\/2012.9.JNS12492","article-title":"Effects of cilostazol on cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a multicenter prospective, randomized, open-label blinded end point trial","volume":"118","author":"Senbokuya","year":"2013","journal-title":"J Neurosurg"},{"issue":"1","key":"10.1016\/j.jocn.2021.12.025_b0070","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000327040","article-title":"Cilostazol improves outcome after subarachnoid hemorrhage: a preliminary report","volume":"32","author":"Suzuki","year":"2011","journal-title":"Cerebrovasc Dis"},{"issue":"6","key":"10.1016\/j.jocn.2021.12.025_b0075","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2176\/nmc.49.235","article-title":"Cilostazol may prevent cerebral vasospasm following subarachnoid hemorrhage","volume":"49","author":"Yoshimoto","year":"2009","journal-title":"Neurol Med Chir"},{"key":"10.1016\/j.jocn.2021.12.025_b0080","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/978-3-319-04981-6_25","article-title":"Cilostazol administration with combination enteral and parenteral nutrition therapy remarkably improves outcome after subarachnoid hemorrhage","volume":"120","author":"Kimura","year":"2015","journal-title":"Acta Neurochir Suppl"},{"issue":"5","key":"10.1016\/j.jocn.2021.12.025_b0085","first-page":"393","article-title":"The efficiency of cilostazol for cerebral vasospasm following subarachnoid hemorrhage","volume":"41","author":"Murahashi","year":"2013","journal-title":"No Shinkei Geka"},{"issue":"6","key":"10.1016\/j.jocn.2021.12.025_b0090","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/ana.25361","article-title":"Cilostazol decreases duration of spreading depolarization and spreading ischemia after aneurysmal subarachnoid hemorrhage","volume":"84","author":"Sugimoto","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jocn.2021.12.025_b0095","doi-asserted-by":"crossref","unstructured":"Nakatsuka Y, Kawakita F, Yasuda R, Umeda Y, Toma N, Sakaida H, Suzuki H. Preventive effects of cilostazol against the development of shunt-dependent hydrocephalus after subarachnoid hemorrhage. J Neurosurg 2017; 127(2):319\u2013326.","DOI":"10.3171\/2016.5.JNS152907"},{"issue":"4","key":"10.1016\/j.jocn.2021.12.025_b0100","doi-asserted-by":"crossref","first-page":"e0230953","DOI":"10.1371\/journal.pone.0230953","article-title":"Effect of treatment modality and cerebral vasospasm agent on patient outcomes after aneurysmal subarachnoid hemorrhage in the elderly aged 75 years and older","volume":"15","author":"Ido","year":"2020","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.jocn.2021.12.025_b0105","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s12975-018-0650-y","article-title":"Dose-dependent inhibitory effects of cilostazol on delayed cerebral infarction after aneurysmal subarachnoid hemorrhage","volume":"10","author":"Suzuki","year":"2019","journal-title":"Transl Stroke Res"},{"issue":"S2","key":"10.1016\/j.jocn.2021.12.025_b0110","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12028-021-01330-0","article-title":"Association between spreading depolarization and delayed cerebral ischemia after subarachnoid hemorrhage: post hoc analysis of a randomized trial of the effect of cilostazol on delayed cerebral ischemia","volume":"35","author":"Kawano","year":"2021","journal-title":"Neurocrit Care"},{"issue":"2","key":"10.1016\/j.jocn.2021.12.025_b0115","first-page":"159","article-title":"Effects of cilostazol and nimodipine combined therapy on delayed cerebral vasospasm after subarachnoid hemorrhage","volume":"40","author":"Wang","year":"2011","journal-title":"J China Med Univ"},{"issue":"20","key":"10.1016\/j.jocn.2021.12.025_b0120","first-page":"42","article-title":"Cilostazol combined with nimodipine in the prevention and treatment of delayed cerebral vasospasm after subarachnoid hemorrhage","volume":"8","author":"Zhu","year":"2017","journal-title":"Heilongjiang Sci"},{"issue":"A01","key":"10.1016\/j.jocn.2021.12.025_b0125","first-page":"377","article-title":"Efficacy of cilostazol combined with nimodipine in the treatment of delayed cerebral vasospasm caused by subarachnoid hemorrhage","volume":"47","author":"Yuan","year":"2018","journal-title":"Chongqing Med"},{"issue":"Pt 2","key":"10.1016\/j.jocn.2021.12.025_b0130","first-page":"43","article-title":"Comparison of intrathecal cilostazol and nimodipine treatments in subarachnoid hemorrhage: an experimental study in rabbits","volume":"110","author":"Onal","year":"2011","journal-title":"Acta Neurochir Suppl"},{"issue":"12","key":"10.1016\/j.jocn.2021.12.025_b0135","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1097\/01.WCB.0000143536.22131.D7","article-title":"The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow","volume":"24","author":"Birk","year":"2004","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"10.1016\/j.jocn.2021.12.025_b0140","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.nbd.2008.07.004","article-title":"Effect of cilostazol on delayed cerebral vasospasm after subarachnoid hemorrhage in rats: evaluation using black blood magnetic resonance imaging","volume":"32","author":"Ito","year":"2008","journal-title":"Neurobiol Dis"},{"issue":"8","key":"10.1016\/j.jocn.2021.12.025_b0145","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1179\/016164109X12608733393791","article-title":"Cilostazol attenuates cerebral vasospasm after experimental subarachnoid hemorrhage","volume":"32","author":"Nishino","year":"2010","journal-title":"Neurol Res"},{"issue":"2","key":"10.1016\/j.jocn.2021.12.025_b0150","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000223439","article-title":"Multifaceted effects of selective inhibitor of phosphodiesterase III, cilostazol, for cerebral vasospasm after subarachnoid hemorrhage in a dog model","volume":"28","author":"Yamaguchi-Okada","year":"2009","journal-title":"Cerebrovasc Dis"},{"issue":"3","key":"10.1016\/j.jocn.2021.12.025_b0155","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s12975-013-0310-1","article-title":"Phenotypic transformation of smooth muscle in vasospasm after aneurysmal subarachnoid hemorrhage","volume":"5","author":"Shimamura","year":"2014","journal-title":"Transl Stroke Res."},{"issue":"1","key":"10.1016\/j.jocn.2021.12.025_b0160","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/jnr.24330","article-title":"Tenascin-C in brain injuries and edema after subarachnoid hemorrhage: Findings from basic and clinical studies","volume":"98","author":"Suzuki","year":"2020","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.jocn.2021.12.025_b0165","doi-asserted-by":"crossref","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343:d5928.","DOI":"10.1136\/bmj.d5928"},{"issue":"9","key":"10.1016\/j.jocn.2021.12.025_b0170","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"issue":"7109","key":"10.1016\/j.jocn.2021.12.025_b0175","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.jocn.2021.12.025_b0180","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1179\/174313208X355495","article-title":"Tenascin-C is induced in cerebral vasospasm after subarachnoid hemorrhage in rats and humans: a pilot study","volume":"32","author":"Suzuki","year":"2010","journal-title":"Neurol Res"},{"key":"10.1016\/j.jocn.2021.12.025_b0185","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-3-319-04981-6_12","article-title":"Effects of tenascin-C on early brain injury after subarachnoid hemorrhage in rats","volume":"120","author":"Shiba","year":"2015","journal-title":"Acta Neurochir Suppl"},{"issue":"3","key":"10.1016\/j.jocn.2021.12.025_b0190","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1007\/s12035-017-0466-x","article-title":"Effects of tenascin-C knockout on cerebral vasospasm after experimental subarachnoid hemorrhage in mice","volume":"55","author":"Fujimoto","year":"2018","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.jocn.2021.12.025_b0195","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-3-319-04981-6_20","article-title":"Tenascin-C is a possible mediator between initial brain injury and vasospasm-related and -unrelated delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage","volume":"120","author":"Suzuki","year":"2015","journal-title":"Acta Neurochir Suppl"},{"key":"10.1016\/j.jocn.2021.12.025_b0200","doi-asserted-by":"crossref","unstructured":"Suzuki H, Kanamaru K, Shiba M, Fujimoto M, Imanaka-Yoshida K, Yoshida T, Taki W. Cerebrospinal fluid tenascin-C in cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Neurosurg Anesthesiol 2011; 23(4):310\u2013317.","DOI":"10.1097\/ANA.0b013e31822aa1f2"},{"key":"10.1016\/j.jocn.2021.12.025_b0205","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-3-319-04981-6_17","article-title":"Vasoconstrictive effect of tenascin-C on cerebral arteries in rats","volume":"120","author":"Fujimoto","year":"2015","journal-title":"Acta Neurochir Suppl"},{"key":"10.1016\/j.jocn.2021.12.025_b0210","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.nbd.2013.01.007","article-title":"Tenascin-C induces prolonged constriction of cerebral arteries in rats","volume":"55","author":"Fujimoto","year":"2013","journal-title":"Neurobiol Dis"},{"issue":"6","key":"10.1016\/j.jocn.2021.12.025_b0215","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.3171\/2015.4.JNS15484","article-title":"Deficiency of tenascin-C and attenuation of blood-brain barrier disruption following experimental subarachnoid hemorrhage in mice","volume":"124","author":"Fujimoto","year":"2016","journal-title":"J Neurosurg"},{"issue":"11","key":"10.1016\/j.jocn.2021.12.025_b0220","doi-asserted-by":"crossref","first-page":"8346","DOI":"10.1007\/s12035-018-1006-z","article-title":"Deficiency of tenascin-C alleviates neuronal apoptosis and neuroinflammation after experimental subarachnoid hemorrhage in mice","volume":"55","author":"Liu","year":"2018","journal-title":"Mol Neurobiol"},{"issue":"1","key":"10.1016\/j.jocn.2021.12.025_b0225","doi-asserted-by":"crossref","first-page":"104485","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.104485","article-title":"Silencing of tenascin-C inhibited inflammation and apoptosis via PI3K\/Akt\/NF-\u03baB signaling pathway in subarachnoid hemorrhage cell model","volume":"29","author":"Tong","year":"2020","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"3","key":"10.1016\/j.jocn.2021.12.025_b0230","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jtcvs.2003.11.015","article-title":"Locally applied cilostazol suppresses neointimal hyperplasia by inhibiting tenascin-C synthesis and smooth muscle cell proliferation in free artery grafts","volume":"128","author":"Fujinaga","year":"2004","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"5","key":"10.1016\/j.jocn.2021.12.025_b0235","first-page":"322","article-title":"Locally applied cilostazol suppresses neointimal hyperplasia and medial thickening in a vein graft model","volume":"13","author":"Yamamoto","year":"2007","journal-title":"Ann Thorac Cardiovasc Surg"},{"issue":"10","key":"10.1016\/j.jocn.2021.12.025_b0240","doi-asserted-by":"crossref","first-page":"e036217","DOI":"10.1136\/bmjopen-2019-036217","article-title":"Efficacy and safety of cilostazol-nimodipine combined therapy on delayed cerebral ischaemia after aneurysmal subarachnoid haemorrhage: a prospective, randomised, double-blinded, placebo-controlled trial protocol","volume":"10","author":"Dawley","year":"2020","journal-title":"BMJ Open"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586821006196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586821006196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:31:22Z","timestamp":1760823082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586821006196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":48,"alternative-id":["S0967586821006196"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2021.12.025","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of cilostazol treatment for patients with aneurysmal subarachnoid hemorrhage: A meta-analysis of 14 studies","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2021.12.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}